the movement of cells is driven by the co-ordinated rearrangement of actin cytoskeleton. Key regulatory proteins of the actin cytoskeleton such as WASP family proteins, Arp2/3 complex, LIM-kinase, cofilin linked the formation of invasive protrusions in cancer cells. 2 MIIP is also thought to contribute in the decreased formation of lamellipodia in endometrial carcinoma cell migration via Rac1. 3 In recent studies, molecules interacting with CasL (MICALs) were reported to participate in cytoskeleton dynamics. [4] [5] [6] The homo sapiens MICAL family consists of three MICAL proteins, (MICAL1-3) and two MICAL-L homologues (MICAL-L1,-L2). MICAL-L2, a member of MICAL family, is present abundantly in ovarian cancer tissues. 7 Silencing of MICAL-L2
could suppress malignancy of ovarian cancer cells by inhibiting canonical Wnt/β-catenin signalling and inducing mesenchymal-epithelial transition. 7 Furthermore, MICAL-L2 was also identified preferentially providing 'law and order' in collective cell migration. 8 Although the results above suggested that MICAL-L2 may be involved in cancer cell invasion and metastasis while our knowledge on functions of MICAL-L2 is limited. Whether and how MICAL-L2 contributes to gastric cancer cell migration remains largely unknown.
Epidermal growth factor receptor (EGFR), a member of the ErbB family, is considered to be overexpressed in gastric cancer and play role in the development of tumourigenesis. 9, 10 Recent evidence
shows that MICAL-L1 mediates EGFR endocytosis, overexpression of MICAL-L1 may lead to the accumulation of EGFR in the late endosomal compartment. 11 MICAL-L2 has been shown to directly implicate in regulating intracellular transport of multiple cell surface receptors and junctional proteins. [12] [13] [14] However, whether MICAL-L2 regulated EGFR endocytosis and recycling pathway remains unclear.
Our data demonstrate that MICAL-L2 inhibited EGFR degradation in lysosome and promoted stable protein level of EGFR, thus results in maintaining the activation of EGFR pathway and cell migrative potential. Moreover, MICAL-L2 was shown to maintain the content of EGFR in Cdc42-dependent manner. Therefore, our findings uncover the contexts in which a recognized cytoskeletal protein MICAL-L2 functions to keep EGFR content and selective inhibition of MICAL-L2 may represent a new potential target for gastric cancer metastasis therapy.
| MATERIAL S AND ME THODS

| Ethics statement
All immunohistochemistry assays with human tumour specimens were conducted under the institutional guidelines of Jiangsu Province.
| Cell culture
Human gastric cancer cell lines SGC-7901, BGC-823 and non-malignant gastric epithelial cell GES-1 were bought from the Cell Biology Institute of Chinese Academy of Sciences (Shanghai, China).
All cells were maintained in Dulbecco's modified Eagle's medium (DMEM, high glucose) (Hyclone, ThermoScientific, Waltham, MA)
supplemented with 10% foetal bovine serum (FBS) (Gibco, Carlsbad, CA), 100 U/mL streptomycin and 100 μg/mL penicillin (Invitrogen, Carlsbad, CA). The cells were incubated at 37°C with 5% CO 2 in a humidified incubator. Cells were grown on coverslips for immunofluorescence staining and on 6-well plates (Costar, Corning, NY) for RNA isolation and protein extraction.
| Plasmids and siRNAs
The pEGFP-N1 vectors containing full-length Cdc42-Q61L
(CA) or Cdc42-T17N (DN) insert were both saved in this laboratory. Human full-length MICAL-L2 cDNA was amplified from pCMV-SPORT6-MICAL-L2 plasmid (YouBio, Hunan, China) using the following primer set, sense: 5′-CTACCGGACTCAGATCT CGAGCCACCATGGCGGCCATCAGGGC-3′ and antisense: 5′-GTAC CGTCGACTGCAGAATTCGCTGGGAGGGGCTGCTTTT-3′. In these primers, XhoI and EcoRI restriction site sequences have been underlined. The PCR products were cloned into the pEGFP-N1 vector (Clontech, Palo Alto, CA). All constructions were ensured by sequencing. Transfection steps were following the manufacturer's protocols, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
The siRNAs were synthesized and purified by China GenePharma Co., and the siRNAs specifically targeting MICAL-L2
were as follows: #1, 5'-GGUUCCCACAAAGAGUAUATT-3′; #2, 
| Cell scratch assays
For scratch assay, a monolayer of cells was cultured in 6-well plate and then a wound space was made manually with 10 µl pipette tip.
After rinsing with PBS, the cell monolayers were treated with indicated stimulator and allowed to migrate for 24 hours. Photographs of wound spaces were taken using microscope (Carl Zeiss Meditec, Jena, Germany).
| Transwell assays
Transwell assay was performed with a 24-well cell culture insert with 
| Real-time quantitative PCR
| Western blotting
Cell lysate was prepared using a total protein extraction buffer (Beyotime, China) and protein concentration was measured using a BCA Protein Assay Kit (Thermo Fisher Scientific, MA) as previously described. 15 Equal amounts of cellular protein lysates were separated by SDS-PAGE electrophoresis and transferred to pure nitrocellulose membrane. After blocking with 5% skim milk, the membrane was 
| Immunofluorescence microscopy
| Pulldown assays
Cells were lysed and Rho GTPase pull-down assays were performed according to the procedures. 16, 17 Active Cdc42/Rac1 was pulldown by PAK-CRIB beads. Briefly, protein lysates were centrifuged and supernatant was collected to new tubes containing beads pre-coupled with PAK-CRIB and incubated under rotation at 4°C for 30 minutes. Then, the beads were washed and the proteins bound on the beads were separated by SDS-PAGE. The amounts of active Cdc42 and Rac1 were determined by Western blot analysis with corresponding antibodies.
| Cell viability assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described. 
| Immunohistochemistry
Gastric cancer tissue microarrays were purchased from Outdo biotech 
| Statistical analysis
All experiments were repeated at least three times independently.
Statistical analysis was performed with the spss statistical software program (Version 19.0; SPSS, Chicago, IL). Data were presented as the means ± SD, the significance of difference in two groups was analysed by Student's t test. Values of P < 0.05 were considered statistical significance and P < 0.01 represents sufficiently statistical significance (two tailed). In immunohistochemistry analysis,
Pearson correlation test was used to show the association between MICAL-L2 and EGFR.
| RE SULTS
| MICAL-L2 is up-regulated and supports EGFR expression in gastric cancer cells
We tested whether MICAL-L2 plays a role in the EGFR expression in gastric cancer cells and determined the specific mechanisms involved.
We first detected the protein levels of MICAL-L2 in malignant and 
| MICAL-L2 positively regulates gastric cancer cell migration
To examine the role of MICAL-L2 in cell motility regulation, both gain-and loss-of-function assays were used to alter MICAL-L2 expression levels in gastric cancer cells. We found that after transfection with MICAL-L2 plasmids, the EGFR expression ( Figure 2A) as well as the migrative potential of SGC-7901 cells were increased ( Figure 2B ). By wound healing and transwell assays, we also noticed the migration of the cells transfected with siMICAL-L2 #2
and #3 were decreased compared with that of control group in BGC-823 ( Figure 2C,D) . These results suggested a positive role for MICAL-L2 in regulating gastric cancer cell migration. We also checked EMT markers expressions, including E-cadherin, N-cadherin and vimentin, after depletion of MICAL-L2 in BGC-823 cells.
The results in Figure 2E showed that silencing of MICAL-L2 increased E-cadherin protein level and decreased, N-cadherin and vimentin levels, implying that MICAL-L2 might play roles in EMT process of gastric cancer cells. To ensure that the inhibitory effects of MICAL-L2 were not caused by a proliferation arrest effect, cells were treated with siMICAL-L2 and their effect on cell viability was determined by MTT assay. The results show that none of the siRNA caused a significant effect on cell viability as compared with control ( Figure 2F ).
| MICAL-L2 supports EGFR expression by preventing EGFR degradation
To investigate the mechanism of EGFR regulation by MICAL-L2, cells were treated with siMICAL-L2 (#2, #3) or MICAL-L2-overexpression plasmids, then analysed for EGFR mRNA level by qPCR.
Whereas SGC-7901 cells underwent markable reduction or increase in MICAL-L2, the abundance of EGFR mRNA was not altered greatly ( Figure 3A,B) . Thus, we concluded that instead of transcription-dependent mechanism, MICAL-L2 may modulate EGFR expression by suppressing its degradation process. As shown in 
| MICAL-L2 prevents lysosome trafficking of EGFR
The degradation of EGFR is regulated by multiple factors. After EGFR binds to ligands, it undergoes dimerization and autophosphorylation. Phosphorylated EGFR then ubiquitinated and enters early and late endosomes in cytoplasm subsequently. Finally, it degrades in lysosomes. The results described above prompted us to determine whether MICAL-L2 is subcellularly localized to cellular organelles.
Immunofluorescence assay showed that EGFR was hardly colocalized with early endosome marker (EEA1), partially colocalized with late endosome (Rab7) and lysosome (LAMP1). We then determined whether EGFR subcellular localization was altered by MICAL-L2 F I G U R E 1 Depletion of MICAL-L2 inhibits EGFR expression in gastric cancer cells. A, BGC-823 cells were transfected with control siRNA or siRNA specifically targeting MICAL-L2 (siMICAL-L2). Forty-eight hours later, total protein extracts from cells were analysed for MICAL-L2 and EGFR expression. Western blot bands corresponding to EGFR and MICAL-L2 were quantified and normalized against GAPDH. **P < 0.01, ***P < 0.001 in the siMICAL-L2 cells relative to siRNA control cells. B, SGC-7901 cells transfected with control siRNA or siMICAL-L2 were lysed, EGFR and MICAL-L2 levels were determined by Western blotting assays. **P < 0.01, ***P < 0.001 in the siMICAL-L2 cells relative to siRNA control cells. C, Representative immunofluorescence images of SGC-7901 cells transfected with control siRNA or siMICAL-L2 staining for EGFR. Scale bar, 5 μm depletion. As shown in immunofluorescent staining in Figure 4A -C,
MICAL-L2 depletion led to decreased colocalization of MICAL-L2
and EGFR in late endosome and increased their colocalization in lysosome, suggesting that knocking down of MICAL-L2 did not affect its entry into the early endosomes, but promoted EGFR translocation from late endosomes into lysosome. These results suggest that MICAL-L2 prevents EGFR degradation, possibly by keeping it away from lysosome-mediated degradation.
| EGFR mediates MICAL-L2-induced cell migration via HSP27 signalling pathways
We further explored the signalling pathways by which MICAL-L2 affects gastric cancer cell migration via EGFR activation.
Stimulation of EGF leads to HSP27 phosphorylation, then the phosphorylated HSP27 is released from the plus end of the actin filament, these processes are important for actin reorganization F I G U R E 2 MICAL-L2 regulates migration of human gastric cancer cells. A, SGC-7901 cells were transfected with empty vector or MICAL-L2 plasmids and the total cellular proteins were extracted and analysed for expressions of EGFR by Western blotting assays. Western blot bands corresponding to EGFR was quantified and normalized against GAPDH. **P < 0.01 in the MICAL-L2 overexpression cells relative to control cells. B, A representative of wound healing assays in SGC-7901 cells transfected with empty vector or MICAL-L2 plasmids is presented and the quantification of cell migration rate was performed (n = 8 for each group). **P < 0.01 in the MICAL-L2 overexpression cells relative to control cells. C, A representative of wound healing assays in BGC-823 cells transfected with control siRNA or siMICAL-L2 is presented and the quantification of cell migration rate was performed (n = 8 for each group) *P < 0.05. D, The migration capacity of BGC-823 cells which transfected with siMICAL-L2 was also evaluated by transwell assays. **P < 0.01 in the siMICAL-L2 cells relative to siRNA control cells. E, BGC-823 cells were transfected with control siRNA or siMICAL-L2, total protein extracts from cells were analysed by Western blotting and bands corresponding to E-cadherin, N-cadherin and vimentin were examined. F, Cell viability of BGC-823 cells transfected with control siRNA or siMICAL-L2 was detected by MTT assays and cell motility. [20] [21] [22] HSP27 is also required for EGF-induced Akt phosphorylation and β-catenin nuclear translocation. 23 As shown in Figure 5A , silencing of MICAL-L2 decreased HSP27 and Akt phosphorylation levels. We identified that Akt was a downstream effector of HSP27 in gastric cancer cells ( Figure S2A ). As shown in Figure 5D , the migration rate of SGC-7901 cells was increased when the cells were transfected with MICAL-L2 plasmids, which was reduced by siHSP27 pre-treatment. These results suggest that MICAL-L2
regulates gastric cancer cell migration by potentiating EGFR-mediated HSP27 signalling pathways.
| MICAL-L2 regulates EGFR stability via Cdc42
It was reported that Cdc42 plays an important role in the pro- 
Cdc42-T17N (inactive mutant) transfection reversed MICAL-L2
overexpression-induced EGFR protein up-regulation ( Figure 6C ).
F I G U R E 3 MICAL-L2 maintains EGFR expression and reduces EGFR degradation. (A, B)
The mRNA levels of MICAL-L2 and EGFR were detected by qPCR in BGC-823 cells transfected with control siRNA and siMICAL-L2 (A) and SGC-7901 cells transfected with empty vectors or MICAL-L2 plasmids (B). C, BGC-823 cells transfected with control siRNA or siMICAL-L2 were in serum-free media overnight and incubated with EGF (20 ng/mL) for 15 min, protein levels of EGFR, P-Akt and P-HSP27 were examined. (D, E) BGC-823 cells transfected with control siRNA or siMICAL-L2 were in serum-free media overnight. After blocking protein synthesis by cycloheximide (CHX, 10 μg/mL), the cells were stimulated with (D) or without (E) EGF (20 ng/mL) for the indicated times. The cells were lysed and EGFR level was determined by Western blotting. GAPDH is used for control. *P < 0.05, **P < 0.01. ***P < 0.001 in the siMICAL-L2 cells relative to siRNA control cells
Effect of MICAL-L2 on EGFR cellular localization. After transfected with control siRNA or siMICAL-2, SGC-7901 cells were immunostained by antibodies against EEA1 (A), Rab7 (B) or LAMP1 (C). All endocytic markers are shown in green. EGFR is shown in red. Nuclei (blue) were visualized by DAPI. The yellow colour indicated the colocalization. Scale bar, 5 μm Furthermore, we found that EGFR level was elevated when Cdc42-Q61L (active mutant) plasmids were transfected into the MICAL-L2-depleted (#2, #3) BGC-823 cells ( Figure 6D ). These results demonstrated that MICAL-L2 promotes gastric cancer cell migration by Cdc42 activity. In summary, we proposed the mechanisms involved in MICAL-L2-regulated gastric cancer cell migration ( Figure 6E ).
| MICAL-L2 was overexpressed in human gastric cancer samples and correlated with EGFR expression
In order to explore whether in vitro experimental results were consistent with the pathogenesis of gastric cancer, we examined the expressions of MICAL-L2 ( Figure 7A ) and EGFR in gastric cancer tissue and its adjacent tissue by a tissue microarray (30 paired 
| D ISCUSS I ON
We demonstrated here that MICAL-L2 plays an important role in gastric cancer cell migration. Our previous work has reported that MICAL2 is the major regulator of breast cancer cell migration through inhibiting EGFR/P38 signalling activation. 24 In the current study, we further extended our observation on MICAL-L2 that lacks flavoprotein monooxygenase (MO) domain and owns C-terminal domains (CTD) compared with MICAL2. 25 We showed that gastric cancer cell migrative potential was greatly impaired, which was likely mediated by the knockdown of MICAL-L2 expression, whereas overexpression of MICAL-L2 increased cell motility. This result is similar to our previous report that MICAL1, via promoting ROS production by its MO domain, controls breast cancer cell invasive phenotype.
26
As MICAL-L2 lacks the MO domain involved in F-actin oxidation and disassembly, the mechanisms underlying the potentiation of gastric cancer cell migration might be different with other MICAL proteins.
F I G U R E 6 MICAL-L2 maintains EGFR content by Cdc42 in gastric cancer cells. A, BGC-823 cells were transfected with siMICAL-L2 and the activity of Cdc42 and Rac1 was measured by pulldown assays. **P < 0.01. B, SGC-7901 cells were transfected with MICAL-L2 plasmids and the activity of Cdc42 was measured by pulldown assays. *P < 0. 23 Stimulation of EGF also led to HSP27 phosphorylation, then the p-HSP27 was released from the plus end of the actin filament. These processes are important for actin reorganization and cell motility. [20] [21] [22] In this study, we noticed that MICAL-L2 overexpression-induced activation of HSP27/ cytoskeleton and HSP27/β-catenin signalling and increased cell migration rate, which were significantly attenuated by the EGFR inhibitor Internalization of EGFR is thought to initiate the termination of the signalling from activated EGFR. The fate of internalized EGFR has important consequences for biological cell outputs. The recycling pathway of EGFR favours cell proliferation, whereas the degradative pathway to lysosomes correlates with cellular homoeostasis. 31, 32 Unliganded EGFR can also be internalized but at much slower rate than liganded receptor. 33 We have previously reported that mucinlike membrane glycoprotein CD24 reduces EGFR internalization and degradation. 34 In this study, our results first clearly indicated that MICAL-L2 existence would give support to the stability of EGFR content in gastric cancer cells that play consistent role with the role of two other members of the MICAL family, MICAL3 and MICAL-L1, in membrane trafficking during cytokinesis. 35, 36 The most important finding here is that MICAL2 identified to be a crucial regulator that links endocytic recycling of EGFR in gastric cancer cells. MICAL-L2
maintains EGFR level through delaying its degradation, but not by inhibiting its production. To our interest, although silencing MICAL-L1
was observed contributes to the distribution of internalized EGFR in vesicles spreading throughout the cytoplasm, 11 and Toca-1. 40 It has been reported to facilitate rapid cell surface turnover at the cell leading edge. 41 Collaboration between Cdc42 and caveolin-1 was shown to mediate endocytosis of silica-coated iron oxide nanoparticles in HeLa cells. 42 In the current study, we 
